Published on September 30, 2009 at 5:42 AM
REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery. In addition to this neurological benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath), the control of which are important therapeutic goals.
The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Experimental Auto Encephalomyelitis,” was published online ahead of print in Neuroscience, 2009 September 24. The publication highlights the statistically significant effects of Tβ4 treatment in EAE mice, including improvement of neurological functional recovery, reduction of inflammatory infiltrates in the brain, and increase of oligodendrocyte progenitor cells (a type of stem cell) and mature oligodendrocytes in the brain.
http://www.regenerx.com/wt/home/index
269ff118-a107-425e-af79-da79b917394d|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Amino Acid, Angiogenesis, Anti-Inflammatory, Brain, Cell, Collagen, Fibrosis, Multiple Sclerosis, Nervous System, Neurology, Neuroscience, Remyelination, Stem Cell, Stroke, Wound Healing